The Golden Lounge

[Theo]

RNN -buying lotto ticket here based on two week old news and price slide- SOMEBODY's gonna pump it again:
SA article

"After extensive research and our insightful interviews with Dr. Peter Suzdak, Chief Executive Officer (CEO) of Rexahn, and with Christopher James, M.D., Managing Director and Senior Research Analyst of Brinson Patrick, we believe the company is significantly undervalued. As the market conditions settle and an uptrend takes effect (which some analysts believe is happening now), a short-term potential gain of 41% (or $0.35) could be realized, representing a pre-market correction price of roughly $1.20 a share. We are encouraged in this claim by the optimism of Dr. Suzdak, who believes that the company is well positioned to achieve a significant number of milestones by year's end, including the completion of both the Supinoxin Phase I and Archexin Phase IIa clinical trials, and enrollment of the Phase Ib trial for RX-3117. We are also encouraged by Dr. James' strong belief that the company will acquire a partnership for RX-3117 by mid-year 2014, as well as his recent coverage initiation on Rexahn at Market Outperform, with an initial 12-month price target of $3.00."